Page 151 - Read Online

immune‑mediated disorders as diabetes mellitus, [58] Benefits of FK506 (tacrolimus) for residual, cyclosporin‑ and
thyroiditis [59] and systemic lupus erythematosis. [60] prednisone‑resistant myasthenia gravis: one‑year follow‑up of an
open‑label study. Clin Neurol Neurosurg 2005;107:187‑90.
13. Pescovitz MD. Rituximab, an anti‑cd20 monoclonal antibody: history
Despite the strength of our findings, this study had and mechanism of action. Am J Transplant 2006;6:859‑66.
some limitations which include: (1) a relatively small 14. Chiu HC, Chen WH, Yeh JH. The six year experience of
sample size that is explained by the fact that we plasmapheresis in patients with myasthenia gravis. Ther Apher
2000;4:291‑5.
included only a homogenous group of adults with 15. Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in
mild/moderate MG in their remission stages and on long‑term treatment of myasthenia gravis. Clin Neurol Neurosurg
maintenance treatment; (2) due to the cross‑sectional 2002;105:3‑8.
nature of the study, the temporal relation between 16. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for
the disease stage and occurrence of cognitive deficits autoimmune myasthenia gravis (an evidence‑based review): report
of the quality standards subcommittee of the American academy of
is difficult to be determined. Future research should neurology. Neurology 2000;55:7‑15.
include longitudinal studies that prospectively 17. Tucker DM, Roeltgen DP, Wann PD, Wertheimer RI. Memory
assess the relation of the disease process to cognition dysfunction in myasthenia gravis: evidence for central cholinergic
effects. Neurology 1988;38:1173‑7.
over time; (3) CSF analysis for determination of 18. Riker WF. Memory impairment in myasthenia gravis. Neurology
immune markers of the disease is missing as our 1989;39:611‑2.
ethical committee did not allow CSF sampling for 19. Iwasaki Y, Kinoshita M, Ikeda K, Takamiya K, Shiojima T. Cognitive
uncomplicated patients. It has been realized that dysfunction in myasthenia gravis. Int J Neurosci 1990;54:29‑33.
CSF examination better detects immune involvement 20. Glennerster A, Palace J, Warburton D, Oxbury S, Newsom‑Davis J.
Memory in myasthenia gravis: neuropsychological tests of central
of CNS, and (4) our investigation did not include cholinergic function before and after effective immunologic
testing for mental fatigue or sleep pattern. These treatment. Neurology 1996;46:1138‑42.
factors cannot be excluded as causes or potentials for 21. Paul RH, Cohen RA, Gilchrist JM, Aloia MS, Goldstein JM. Cognitive
cognitive dysfunction with MG. dysfunction in individuals with myasthenia gravis. J Neurol Sci
2000;179:59‑64.
22. Hokkanen E, Toivakka E. Electroencephalographic findings in
In conclusion, adults with mild/moderate MG may myasthenia gravis 180 EEG recordings of 109 patients. Acta Neurol
experience prominent cognitive deficits in different Scand 1969;45:556‑67.
domains regardless to the presence of depression. This 23. Tartara A, Mola M, Manni R, Moglia A, Lombardi M, Poloni M,
Piccolo G. EEG findings in 118 cases of myasthenia gravis. Rev
is important to determine prognosis and managing Electroencephalogr Neurophysiol Clin 1982;12:275‑9.
patients. 24. Kazis A, Pappa P, Xafenias D. EEG finding in myasthenia gravis.
Electromyogr Clin Neurophysiol 1984;24:577‑82.
REFERENCES 25. Feldmann R, Kiefer R, Wiegard U, Evers S, Weglage J. Intelligence,
attention, and memory in patients with myasthenia gravis.
Nervenarzt 2005;76:960, 962‑6.
1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. 26. Marra C, Marsili F, Quaranta D, Evoli A. Determinants of cognitive
Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, impairment in elderly myasthenia gravis patients. Muscle Nerve
clinical correlates, and diagnostic value. Neurology 1976;26:1054‑9. 2009;40:952‑9.
2. Phillips LH 2 . The epidemiology of myasthenia gravis. Neurol Clin 27. Sitek EJ, Bilinska MM, Wieczorek D, Nyka WM. Neuropsychological
nd
1994;12:263‑71. assessment in myasthenia gravis. Neurol Sci 2009;30:9‑14.
3. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797‑810. 28. Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis
4. Engel AG. Disturbances in neuromuscular transmission. In: with autoimmune autonomic neuropathy. Auton Neurosci
Engel AG, Franzini‑Armstrong C, editors. Myology. 2 ed. New York: 2001;88:187‑92.
nd
McGraw‑Hill; 1994. p. 1769‑97. 29. Gotkine M, Fellig Y, Abramsky O. Occurrence of CNS demyelinating
5. Onodera H. The role of the thymus in the pathogenesis of disease in patients with myasthenia gravis. Neurology 2006;67:881‑3.
myasthenia gravis. Tohoku J Exp Med 2005;207:87‑98. 30. Hamed SA. Comorbid nervous system manifestations and disorders
6. Scheife RT, Hills JR, Munsat TL. Myasthenia gravis: signs, symptoms, with myasthenia gravis: evidences and possible mechanisms.
diagnosis, immunology, and current therapy. Pharmacotherapy J Neurol Neurosci 2012;3:2.
1981;1:39‑54. 31. Stepansky R, Weber G, Zeitlhofer J. Sleep apnea in myasthenia
7. Bedlack RS, Sanders DB. Steroid treatment for myasthenia gravis: gravis. Wien Med Wochenschr 1996;146:209‑10.
steroids have an important role. Muscle Nerve 2002;25:117‑21. 32. Amino A, Shiozawa Z, Nagasaka T, Shindo K, Ohashi K, Tsunoda S,
8. Palace J, Newsom‑Davis J, Lecky B. A randomized double‑blind Shintani S. Sleep apnoea in well‑controlled myasthenia gravis and
trial of prednisolone alone or with azathioprine in myasthenia gravis. the effect of thymectomy. J Neurol 1998;245:77‑80.
Myasthenia Gravis Study Group. Neurology 1998;50:1778‑83. 33. Nicolle MW, Rask S, Koopman WJ, George CF, Adams J, Wiebe S.
9. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical Sleep apnea in patients with myasthenia gravis. Neurology
therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad 2006;67:140‑2.
Sci 1993;681:539‑51. 34. Lewis SW, Ron MA, Newsom‑Davis J. Absence of central functional
10. Chaudhry V, Cornblath DR, Griffin JW, O’Brien R, Drachman DB. cholinergic deficits in myasthenia gravis. J Neurol Neurosurg
Mycophenolate mofetil: a safe and promising immunosuppressant Psychiatry 1989;52:258‑61.
in neuromuscular diseases. Neurology 2001;56:94‑6. 35. Paul RH, Cohen RA, Zawacki T, Gilchrist JM, Aloia MS. What
11. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory have we learned about cognition in myasthenia gravis?: a review
myasthenia: “rebooting” with high‑dose cyclophosphamide. Ann of methods and results. Neurosci Biobehav Rev 2001;25:75‑81.
Neurol 2003;53:29‑34. 36. Paul RH, Cohen RA, Gilchrist JM. Ratings of subjective mental
12. Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M. fatigue relate to cognitive performance in patients with myasthenia

Neuroimmunol Neuroinflammation | Volume 1 | Issue 3 | December 2014 145